Seer, Inc. (SEER)

NASDAQ: SEER · Real-Time Price · USD
2.190
-0.010 (-0.45%)
At close: Aug 13, 2025, 4:00 PM
2.170
-0.020 (-0.91%)
After-hours: Aug 13, 2025, 4:00 PM EDT
-0.45%
Market Cap 128.69M
Revenue (ttm) 16.29M
Net Income (ttm) -82.44M
Shares Out 58.76M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 85,524
Open 2.190
Previous Close 2.200
Day's Range 2.160 - 2.190
52-Week Range 1.585 - 2.625
Beta 1.58
Analysts Hold
Price Target 3.00 (+36.99%)
Earnings Date Aug 6, 2025

About SEER

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratori... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 4, 2020
Employees 134
Stock Exchange NASDAQ
Ticker Symbol SEER
Full Company Profile

Financial Performance

In 2024, Seer, Inc.'s revenue was $14.17 million, a decrease of -14.95% compared to the previous year's $16.66 million. Losses were -$86.60 million, 0.37% more than in 2023.

Financial Statements

Analyst Forecast

According to one analyst, the rating for SEER stock is "Hold" and the 12-month stock price target is $3.0.

Price Target
$3.0
(36.99% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Seer, Inc. (SEER) Q2 2025 Earnings Call Transcript

Seer, Inc. (NASDAQ:SEER) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants David R. Horn - President,Treasurer & CFO Kelly Gura - Corporate Participant Omid C.

6 days ago - Seeking Alpha

Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph ® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 0...

7 days ago - GlobeNewsWire

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be parti...

13 days ago - GlobeNewsWire

Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial ...

22 days ago - GlobeNewsWire

Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics

2 months ago - GlobeNewsWire

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteogra...

2 months ago - GlobeNewsWire

Seer, Inc. (SEER) Q1 2025 Earnings Call Transcript

Seer, Inc. (NASDAQ:SEER) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Kelly Gura - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of the Board D...

3 months ago - Seeking Alpha

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Revenue grew 37%, driven by increased product sales and service revenue Revenue grew 37%, driven by increased product sales and service revenue

3 months ago - GlobeNewsWire

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wi...

3 months ago - GlobeNewsWire

Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript

Seer, Inc. (NASDAQ:SEER) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of ...

5 months ago - Seeking Alpha

Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial re...

5 months ago - GlobeNewsWire

Seer to Participate in the TD Cowen 45th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

6 months ago - GlobeNewsWire

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using ...

6 months ago - GlobeNewsWire

Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil...

6 months ago - GlobeNewsWire

Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference

REDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

7 months ago - GlobeNewsWire

Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease Attributes 2,440% ...

9 months ago - GlobeNewsWire

Seer to Participate in Upcoming November Investor Conferences

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management ...

9 months ago - GlobeNewsWire

Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript

Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript

9 months ago - Seeking Alpha

Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific

Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology Collaboration enhances unprecedented access to deep, unbiased proteomics ...

10 months ago - GlobeNewsWire

Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024

CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite CoLab session with...

10 months ago - GlobeNewsWire

Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024

Seer's Proteograph™ Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthro...

10 months ago - GlobeNewsWire

Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

1 year ago - GlobeNewsWire

Seer Appoints Nicolas Roelofs to its Board of Directors

REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appo...

1 year ago - GlobeNewsWire

Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference

REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

1 year ago - GlobeNewsWire

Seer to Report Second Quarter 2024 Financial Results on August 8, 2024

REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil...

1 year ago - GlobeNewsWire